Login / Signup

Regulatory, scientific, and ethical issues arising from institutional activity in one of the 90 Italian Research Ethics Committees.

G Benfattonull nullnull nullFilippo Drago
Published in: BMC medical ethics (2021)
Preventive measures are needed to reduce the number of requested corrections and thus also the time required for approval, while maintaining review quality. All critical points and proposals presented in this paper require harmonization through updates to European regulations, as regulatory harmonization produces better compliance with rules and reduces the number of changes required before the trials' final approval. Such updates include the development of standardized formats for informed consent, the verification of any evidence in favor of using off-label treatments over placebo as comparators, using multidisciplinary staff in clinical trials with children and adolescents, improving the legal definition of RECs to assign responsibilities and ensure independence, and providing guidance for RECs to engage clinical research assistants in internal audits.
Keyphrases
  • clinical trial
  • transcription factor
  • drug administration
  • public health
  • quality improvement
  • phase iii
  • double blind
  • randomized controlled trial
  • phase ii
  • decision making
  • open label
  • global health
  • placebo controlled